GlassScriptPhysician profile
Justin A Ossman
NPI 1982946091
$3,186.05
in general payments reported to CMS, 2019-2025
28 companies · $968 in 2025
The $968 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $72.45 · 2022: $461 · 2023: $462 · 2024: $947 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $585.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $494.79 | 2022-2025 | |
| Pfizer INC. | $331.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $264.80 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $206.99 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.82 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $128.99 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $118.21 | 2024-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $100.44 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.10 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $66.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $64.06 | 2019-2022 | |
| Dexcom, INC. | $58.76 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $58.62 | 2024-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $54.72 | 2022-2024 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.52 | 2023-2025 | Eliquis |
| Inspire Medical Systems, INC. | $46.78 | 2024-2025 | Inspire |
| Lilly USA, LLC | $46.06 | 2022-2024 | Jardiance |
| Medtronic, INC. | $41.15 | 2023-2025 | Inceptiv, Accurian |
| Ironshore Pharmaceuticals INC. | $40.65 | 2024 | |
| Antares Pharma, INC. | $36.37 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Ironwood Pharmaceuticals, INC | $30.45 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $27.48 | 2022-2025 | Zoryve |
| Corium, LLC | $24.24 | 2024 | Azstarys |
| Axsome Therapeutics, INC. | $21.35 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $17.13 | 2023 | Quviviq |
| Exact Sciences Corporation | $16.40 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.79 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Ossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.